Dr. Michael Wolfe’s Laboratory
Professor
Education:
MD – Ohio State University
General field of research:
Gastrointestinal Regulatory Peptides
Affiliations other than medicine:
Evans Center for Interdisciplinary Biomedical Research
Research Professor of Physiology and Biophysics
Contact information:
Office
650 Albany Street, Room 504
Phone: (617) 638-8330
Lab
650 Albany Street, Room 520
Phone: (617) 638-8215
Fax: (617) 638-7785
Research group information
Michael Boylan, PhD
Lisa Jepeal, BS
Daniel Prabakaran, PhD
Keywords:
GIP Obesity; COX-2
Summary of research interest:
The major interest in Dr. Wolfe’s laboratory has always revolved around the physiological and pathological significance of gastrointestinal regulatory peptides. His lab has been conducting investigation aimed at determining the physiological and pathological significance of glucose-dependent insulinotropic polypeptide (GIP). Presently, the lab is investigating the role of GIP in lipid homeostasis and intestinal nutrient absorption. He and his colleagues recently also identified GIP receptors on various malignant cell lines, and they have demonstrated that GIP, which is overexpressed in obesity, increases the proliferation of these cells. Accordingly, the lab has initiated studies to evaluate the role of GIP in obesity-related carcinogenesis. Finally, he and his collaborators are conducting studies aimed at developing methods to program stem cells to synthesize insulin and other therapeutic peptides. They plan to eventually introduce these programmed cells into the upper small intestine, where they will engraft and synthesize and release the peptide into the circulation to treat type 1 diabetes mellitus and other deficiency states.
Recent publications:
Jepeal LI, Fujitani Y, Boylan MO, Wilson CN, Wright CV, Wolfe MM. 2005. Cell-specific expression of glucose-dependent insulinotropic polypeptide (GIP) requires the transcription factor PDX-1. Endocrinology 146:383-391. PMCID:15486225
Song DH, Kaufman JC, Borodyansky L, Albanese C, Pestell RG, Wolfe MM. 2005. Gastrin stabilises beta-catenin protein in mouse colorectal cancer cells. Br J Cancer 25:1581-1587. PMCID:15798764
Boylan MO, Jepeal JI, Wolfe MM. 2006. Sp1/Sp3 binding is associated with cell-specific expression of the glucose-dependent insulinotropic polypeptide receptor gene. Am J Physiol 290:E1287-E1295. PMCID:16403775
Getty-Kaushik L , Song DH, Boylan MO, Corkey B, Wolfe MM. 2006. A receptor specific antagonist reverses the insulin mimetic properties of glucose-dependent insulinotropic polypeptide (GIP) on lipolysis and triglyceride synthesis in perifused rat adipocytes. Obesity 14:1124-1131. PMCID:16899793
Chang AJ, Song DH, Wolfe MM. 2006. Gastrin stimulation of colorectal cancer cell proliferation is mediated in part by attenuation of peroxisome proliferator activated receptor gamma (PPAR ) activity and proteasomal degradation of PPARγ protein. J Biol Chem 281:14700-14710. PMCID:16574647
Song DH, Getty-Kaushik L , Tseng E, Simon, J, Corkey BE, Wolfe MM. 2007. Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. Gastroenterology 133:1796-1805. PMCID:2185546
Jepeal LI, Boylan MO, Wolfe MM. 2008. GATA-4 upregulates glucose-dependent insulinotropic polypeptide expression in cells of pancreatic and intestinal lineage. Mol Cell Endocrinol 287:20-29. PMCID:18343025
